User menu

Pergolide associated valvulopathies, a Belgian experience

Bibliographic reference Evrard, F. ; Dupuis, Michel. Pergolide associated valvulopathies, a Belgian experience.6th Annual Meeting of the International-Society-of-Pharmacovigilance (Liege (Belgium), Oct 11-13, 2006). In: Drug Safety, Vol. 29, no. 10, p. 972-972 (2006)
Permanent URL http://hdl.handle.net/2078.1/59918
  1. Baseman D. G., O'Suilleabhain P. E., Reimold S. C., Laskar S. R., Baseman J. G., Dewey R. B., Pergolide use in Parkinson disease is associated with cardiac valve regurgitation, 10.1212/01.wnl.0000129842.49926.07
  2. Mayo Clin Proc, 78, 730 (2003)
  3. Van Camp G., Flamez A., Cosyns B., Goldstein J., Perdaens C., Schoors D., Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide, 10.1212/01.wnl.0000083985.00343.f2
  4. Rothman R. B., Baumann M. H., Savage J. E., Rauser L., McBride A., Hufeisen S. J., Roth B. L., Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications, 10.1161/01.cir.102.23.2836